Categories: All postsAnalysts

Catamaran takeover bid by UnitedHealth gets thumbs up at Cantor Fitzgerald

The proposed OptumRx (UnitedHealth Group) offer to buy Catamaran (Catamaran Stock Quote, Chart, News: TSX:CCT, Nasdaq:CTRX) is a good deal for both parties, says Cantor Fitzgerald Canada analyst Justin Kew.

In a research update to clients this morning, Kew moved his rating on Catamaran to “Tender” from “Buy” and raised his target price on the stock to the offer price of $61.50, from his previous $60.00.

This morning, Catamaran and UnitedHealth Group announced that Catamaran and OptumRx, UnitedHealth’s free-standing pharmacy care services business, had agreed to merge.

“Our board of directors carefully considered a variety of strategic options and unanimously concluded that this combination is clearly in the best interests of our shareholders,” said Catamaran CEO Mark Thierer. “The creation of a differentiated, channel-agnostic delivery model will provide payers and individuals a broader portfolio of services and a deeper product offering while aggressively focusing on managing costs. Together, we believe we will have the talent, scale, technology resources and innovative spirit to build the most modern, effective and consumer-focused PBM in the history of the industry.”

Kew says the 17x TTM EV/EBITDA and 14x FTM EV/EBITDA valuation of the deal is attractive for Catamaran shareholders. He also thinks the scenario of other bidders arising is unlikely because of potential antitrust issues from Express Scripts and CVS Caremark, given the size of their respective market shares.

The analyst says today’s deal effectively creates a third major player in the Pharmacy Benefit Management space.

“The CTRX acquisition will more than double OptumRx’s script count from 0.4 billion to 1.0 billion scripts per year. We estimate that OptumRx’s market share (by script count) increases from 14% to 23%, moving it to the third largest PBM behind CVS Caremark at 25% and Express Scripts at 31%.,” he said.

The proposed purchase price of $61.50 per share in cash is a 27% premium to Catamaran’s Friday’s close of $48.35.

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

Nick Waddell

Cantech Letter founder and editor Nick Waddell has lived in five Canadian provinces and is proud of his country's often overlooked contributions to the world of science and technology. Waddell takes a regular shift on the Canadian media circuit, making appearances on CTV, CBC and BNN, and contributing to publications such as Canadian Business and Business Insider.

Recent Posts

Should you buy AMZN? (May, 2024)

Following the company's first quarter results, Roth MKM analyst Rohit Kulkarni has maintained his "Buy" rating on Amazon (Amazon Stock… [Read More]

9 hours ago

These cannabis stocks will benefit most from reclassification

It happened. The move that everyone in the cannabis sector was hoping for came about swiftly on the last day… [Read More]

16 hours ago

Is AMD stock a buy? (May, 2024)

Following the company's first quarter results, Roth MKM analyst Suji Desilva has maintained his "Buy" rating on Advanced Micro Devices… [Read More]

17 hours ago

Is Wolfspeed stock still a buy?

Ahead of the company's third quarter results, Roth MKM analyst Scott Irwin has maintained his "Buy" rating on Wolfspeed (Wolfspeed… [Read More]

18 hours ago

WELL Health inks five-year deal with Microsoft

It's become one of the biggest players in the Canadian healthcare space, now WELL Health (WELL Health Stock Quote, Chart,… [Read More]

2 days ago

Is Thomson Reuters stock a buy right now?

Its stock has made a since last October, but is there more upside left in Thomson Reuters (Thomson Reuters Stock… [Read More]

2 days ago